Puneet Varma (Editor)

XF 73

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
PubChem CID  9918582
Molar mass  765.82 g·mol−1
ChemSpider ID  8094227

XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls. It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.

Structurally it is a dicationic porphyrin.

It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.

In 2014 a phase 1 clinical trial for nasal administration was run.

As of February 2016 another phase 1 clinical trial (for nasal administration) is recruiting.

References

XF-73 Wikipedia


Similar Topics
Andreï Makine
Mario Scheiber
Rune Jansson
Topics
 
B
i
Link
H2
L